The Biomarker Senior Scientist is responsible for discovery, assay development and assay transfer for disease and drug related biomarkers including those for patient stratification and indication expansion. This strategy is critical to Annexon’s precision medicine approach in the key therapeutic areas of Autoimmune diseases, Neuroscience and Ophthalmology. This individual will serve as an important integrator between research and development. This position is 50% effort working in the laboratory.
Responsibilities
Align biomarker discovery efforts with the clinical biomarker leads and therapeutic area heads.
Drive biomarker identification, assay development and preclinical validation in Autoimmune disease, Neuroscience and Ophthalmology
Oversee both internal and external work as appropriate
Support preclinical pharmacology studies as needed
Author IND enabling regulatory documents
Maintain awareness and assess new Biomarker technologies
Qualifications
PhD and/or post-doc training in the area of neuroscience or immunology, or other related medical science field with a minimum of 8 years of relevant biotechnology or pharmaceutical industry experience.
Knowledge of biomarker discovery and development, assay development/validation, and MoA/translational research.
Experience assay development for PK, PD anti-drug antibodies a must
Strong experimental background and experience in hypothesis-driven biological/translational research with demonstrated ability to execute well-designed experiments.
Ability to integrate complex scientific ideas, generate testable hypotheses, and execute well controlled experiments
Candidate must be detail-oriented with excellent record keeping and organizational skills.
Must be a highly flexible, results oriented, independent scientist who enjoys working in a fast-paced and dynamic, team-oriented, and collaborative environment.
Must be comfortable with working in a highly matrixed environment where influencing without authority is routine
Preferred Qualification
Experience with assay development for small molecules desirable
About Annexon Biosciences
Annexon Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The Company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The Company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The Company’s second product candidate, ANX007, is a monoclonal antibody antigen-binding fragment (Fab) formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Based on learnings from its initial trials, Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that each of its product candidates is engaging the specific target at a well-tolerated therapeutic dose in the intended patient tissue.
